PMID 24112036
In contrast, GLP-1-R agonists effectively reduce stroke events in patients with T2DM and established ASCVD, and thus have been implemented into recommendations for the stroke prevention of several associations, such as the American Stroke Association [9]
A January 2025 cross-sectional study found that of 79 websites selling compounded medications, nearly half didnt report known adverse effects (including nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis, and gallstones) and warnings for compounded GLP-1s
GLP-1 agonists work by mimicking a natural hormone in your body that regulates appetite and food intake, often leading to reduced hunger
Oral GLP-1 receptor agonists are also in the development phase, with preliminary data showing efficacy similar to that of Semaglutide